The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process

Cancer Research

Volumn 63, Issue 8, 2003, Pages 1822-1833

  Yu, Chunrong ^a   Rahmani, Mohamed ^a   Dai, Yun ^a   Conrad, Daniel ^a   Krystal, Geoffrey ^a   Dent, Paul ^a   Grant, Steven ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; APOPTOSIS INDUCING FACTOR; CAFFEINE; CASPASE; CASPASE 8; CGP 74514 A; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOCHROME C; FLAVOPIRIDOL; INHIBITOR OF APOPTOSIS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; NCS 649890; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE; PROTEIN KINASE C; PROTEIN P70; RAPAMYCIN; ROSCOVITINE; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; WORTMANNIN;

APOPTOSIS; ARTICLE; CELL STRAIN HL 60; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RAJI CELL; TUMOR SUPPRESSOR GENE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; 2-AMINOPURINE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CHROMONES; CYCLIN-DEPENDENT KINASES; DRUG SYNERGISM; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; LEUKEMIA; MORPHOLINES; PIPERIDINES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PURINES; TUMOR CELLS, CULTURED;

EID: 0037446980     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Sherr, C. J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res., 60: 3689-3695, 2000.
2. Morgan, D. O. Cell cycle control in normal and neoplastic cells. Curr. Opin. Genet. Dev., 2: 33-37, 1992.
3. Nurse, P. A long twentieth century of the cell cycle and beyond. Cell, 100: 71-78, 2000.
4. Kishimoto, T., and Okumura, E. In vivo regulation of the entry into M-phase: initial activation and nuclear translocation of cyclin B/Cdc2. Prog. Cell Cycle Res., 3: 241-249, 1997.
5. De Azevedo, W. F., Jr., Mueller-Dieckmann, H. J., Schulze-Gahmen, U., Worland, P. J., Sausville, E., and Kim, S. H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA, 93: 2735-2740, 1996.
6. Sedlacek, H. H. Mechanisms of action of flavopiridol. Crit. Rev. Oncol. Hematol., 38: 139-170, 2001.
7. Chao, S. H., and Price, D. H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem., 276: 31793-31799, 2001.
8. Senderowicz, A. M., and Sausville, E. A. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. (Bethesda), 92: 376-387, 2000.
9. Dai, Y., Dent, P., and Grant, S. Induction of apoptosis in human leukemia cells by the CDK1 inhibitor CGP74514A. Cell Cycle. 1: 143-152, 2002.
10. Evan, G. I., and Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. Nature (Lond.), 411: 342-348, 2001.
11. Bible, K. C., and Kaufmann, S. H. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res., 56: 4856-4861, 1996.
12. Parker, B. W., Kaur, G., Nieves-Neira, W., Taimi, M., Kohlhagen, G., Shimizu, T., Losiewicz, M. D., Pommier, Y., Sausville, E. A., and Senderowicz, A. M. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood, 91, 458-465, 1998.
13. Mgbonyebi, O. P., Russo, J., and Russo, I. H. Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells. Cancer Res., 59: 1903-1910, 1999.
14. Edamatsu, H., Gau, C. L., Nemoto, T., Guo, L., and Tamanoi, F. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene, 19: 3059-3068, 2000.
15. Carlson, B., Lahusen, T., Singh, S., Loaiza-Perez, A., Worland, P. J., Pestell, R., Albanese, C., Sausville, E. A., and Senderowicz, A. M. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res., 59: 4634-4641, 1999.
16. Kitada, S., Zapata, J. M., Andreeff, M., and Reed, J. C. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood, 96: 393-397, 2000.
17. Decker, R. H., Dai, Y., and Grant, S. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death Differ., 8: 715-724, 2001.
18. Reed, J. C. Bcl-2 family proteins. Oncogene, 17: 3225-3236, 1998.
19. Widmann, C., Gibson, S., Jarpe, M. B., and Johnson, G. L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol. Rev., 79: 143-180, 1999.
20. Brunet, A., and Pouyssegur, J. Mammalian MAP kinase modules: how to transduce specific signals. Essays Biochem., 32: 1-16, 1997.
21. Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., and Greenberg, M. E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science (Wash. DC), 270: 1326-1331, 1995.
22. Cantley, L. C. The phosphoinositide 3-kinase pathway. Science (Wash. DC), 296: 1655-1657, 2002.
23. Vanhaesebroeck, B., and Waterfield, M. D. Signaling by distinct classes of phosphoinositide 3-kinases. Exp. Cell Res., 253: 239-254, 1999.
24. Vanhaesebroeck, B., and Alessi, D. R. The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J., 346: 561-576, 2000.
25. Nicholson, K. M., and Anderson, N. G. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal., 14: 381-395, 2002.
26. Datta, S. R., Brunet, A., and Greenberg, M. E. Cellular survival: a play in three Akts. Genes Dev., 13: 2905-2927, 1999.
27. Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., and Reed, J. C. Regulation of cell death protease caspase-9 by phosphorylation. Science (Wash. DC), 282: 1318-1321, 1998.
28. Nakamura, N., Ramaswamy, S., Vazquez, F., Signoretti, S., Loda, M., and Sellers, W. R. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol. Cell. Biol., 20: 8969-8982, 2000.
29. Standaert, M. L., Bandyopadhyay, G., and Farese, R. V. Studies with wortmannin suggest a role for phosphatidylinositol 3-kinase in the activation of glycogen synthase and mitogen-activated protein kinase by insulin in rat adipocytes: comparison of insulin and protein kinase C modulators. Biochem. Biophys. Res. Commun., 209: 1082-1088, 1995.
30. Sanchez-Margalet, V., Goldfine, I. D., Vlahos, C. J., and Sung, C. K. Role of phosphatidylinositol-3-kinase in insulin receptor signaling: studies with inhibitor, LY294002. Biochem. Biophys. Res. Commun., 204: 446-452, 1994.
31. Cartee, L., Smith, R., Dai, Y., Rahmani, M., Rosato, R., Almenara, J., Dent, P., and Grant, S. Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways. Mol. Pharmacol., 61: 1313-1321, 2002.
32. Jarvis, W. D., Fornari, F. A., Traylor, R. S., Martin, H. A., Kramer, L. B., Erukulla, R. K., Bittman, R., and Grant, S. Induction of apoptosis and potentiation of ceramide-mediated cytotoxicity by sphingoid bases in human myeloid leukemia cells. J. Biol. Chem., 271: 8275-8284, 1996.
33. Yu, C., Wang, S., Dent, P., and Grant, S. Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway. Mol. Pharmacol., 60: 143-154, 2001.
34. Grant, S., Traylor, R., Bhalla, K., McCrady, C., and Pettit, G. R. Effect of a combined exposure to cytosine arabinoside, bryostatin 1, and recombinant granulocytemacrophage colony-stimulating factor on the clonogenic growth in vitro of normal and leukemic human hematopoietic progenitor cells. Leukemia (Baltimore), 6: 432-439, 1992.
35. Chou, T. C., and Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
36. Jacobson, M. D., Burne, J. F., and Raff, M. C. Mechanisms of programmed cell death and Bcl-2 protection. Biochem. Soc. Trans., 22: 600-602, 1994.
37. Decker, R., Wang, S., and Grant, S. Loss of the N-terminal phosphorylation loop domain is required to protect human leukemia cells (U937) overexpressing Bcl-2 from flavopiridol-induced lethality. Cancer Biol. Ther., 1: 136-147, 2002.
38. Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., Copeland, R. A., Magolda, R. L., Scherle, P. A., and Trzaskos, J. M. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem., 273: 18623-18632, 1998.
39. Simon, C., Goepfert, H., and Boyd, D. Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. Cancer Res., 58: 1135-1139, 1998.
40. Hosoi, H., Dilling, M. B., Shikata, T., Liu, L. N., Shu, L., Ashmun, R. A., Germain, G. S., Abraham, R. T., and Houghton, P. J. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res., 59: 886-894, 1999.
41. Post, S. R., Aguila-Buhain, O., and Insel, P. A. A key role for protein kinase A in homologous desensitization of the β2-adrenergic receptor pathway in S49 lymphoma cells. J. Biol. Chem., 271: 895-900, 1996.
42. Toullec, D., Pianetti, P., Coste, H., Bellevergue, P., Grand-Perret, T., Ajakane, M., Baudet, V., Boissin, P., Boursier, E., and Loriolle, F. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem., 266: 15771-15781, 1991.
43. Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., Bhagwat, S. S., Manning, A. M., and Anderson, D. W. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA, 98: 13681-13686, 2001.
44. Graves, P. R., Yu, L., Schwarz, J. K., Gales, J., Sausville, E. A., O'Connor, P. M., and Piwnica-Worms, H. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem., 275: 5600-5605, 2000.
45. Dai, Y., Yu, C., Singh, V., Tang, L., Wang, Z., McInistry, R., Dent, P., and Grant, S. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/ MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res., 61: 5106-5115, 2001.
46. Meijer, L., Borgne, A., Mulner, O., Chong, J. P., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J. G., and Moulinoux, J. P. Biochemical and cellular effects of roscovitine. a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem., 243: 527-536, 1997.
47. Havlicek, L., Hanus, J., Vesely, J., Leclerc, S., Meijer, L., Shaw, G., and Strnad, M. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J. Med. Chem., 40: 408-412, 1997.
48. Banin, S., Moyal, L., Shieh, S., Taya, Y., Anderson, C. W., Chessa, L., Smorodinsky, N. I., Prives. C., Reiss, Y., Shiloh, Y., and Ziv, Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science (Wash. DC), 281: 1674-1677, 1998.
49. Fukuchi, K., Watanabe, H., Tomoyasu, S., Ichimura, S., Tatsumi, K., and Gomi, K. Phosphatidylinositol 3-kinase inhibitors. Wortmannin or LY294002, inhibited accumulation of p21 protein after γ-irradiation by stabilization of the protein. Biochim. Biophys. Acta, 1496: 207-220, 2000.
50. Sidhu, J. S., Liu, F., Boyle, S. M., and Omiecinski, C. J. PI3K inhibitors reverse the suppressive actions of insulin on CYP2E1 expression by activating stress-response pathways in primary rat hepatocytes. Mol. Pharmacol., 59: 1138-1146, 2001.
51. Cheng, E. H., Wei, M. C., Weiler, S., Flavell, R. A., Mak, T. W., Lindsten, T., and Korsmeyer, S. J. BCL-2. BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell, 8: 705-711, 2001.
52. Chauhan, D., Hideshima, T., Rosen, S., Reed, J. C., Kharbanda, S., and Anderson, K. C. Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J. Biol. Chem., 276: 24453-24456, 2001.
53. Wu, G., Chai, J., Suber, T. L., Wu, J. W., Du, C., Wang, X., and Shi, Y. Structural basis of IAP recognition by Smac/DIABLO. Nature (Lond.), 408: 1008-1012, 2000.
54. Carson, J. P., Behnam, M., Sutton, J. N., Du, C., Wang, X., Hunt, D. F., Weber, M. J., and Kulik, G. Smac is required for cytochrome c-induced apoptosis in prostate cancer LNCaP cells. Cancer Res., 62: 18-23, 2002.
55. Sun, X. M., MacFarlane, M., Zhuang, J., Wolf, B. B., Green, D. R., and Cohen, G. M. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J. Biol. Chem., 274: 5053-5060, 1999.
56. Nicholson, K. M., and Anderson, N. G. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal., 14: 381-395, 2002.
57. Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M. E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 91: 231-241, 1997.
58. Leverrier, Y., Thomas, J., Mathieu, A. L., Low, W., Blanquier, B., and Marvel, J. Role of P13-kinase in Bcl-X induction and apoptosis inhibition mediated by IL-3 or IGF-1 in Baf-3 cells. Cell Death Differ., 6: 290-296, 1999.
59. Pap, M., and Cooper, G. M. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J. Biol. Chem., 273: 19929-19932, 1998.
60. Edinger, A. L., and Thompson, C. B. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell, 13: 2276-2288, 2002.
61. Gelfanov, V. M., Burgess, G. S., Litz-Jackson, S., King, A. J., Marshall, M. S., Nakshatri, H., and Boswell, H. S. Transformation of interleukin -3-dependent cells without participation of Stat5/bcl-xL: cooperation of akt with raf/erk leads to p65 nuclear factor κB-mediated antiapoptosis involving c-IAP2. Blood, 98: 2508-2517, 2001.
62. Semenov, I., Akyuz, C., Roginskaya, V., Chauhan, D., and Corey, S. J. Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol. Leuk. Res., 26: 271-280, 2002.
63. del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R., and Nunez, G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science (Wash. DC), 278: 687-689, 1997.
64. Hu, L., Hofmann, J., Lu, Y., Mills, G. B., and Jaffe, R. B. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res., 62: 1087-1092, 2002.
65. O'Gorman, D. M., McKenna, S. L., McGahon, A. J., Knox, K. A., and Cotter, T. G. Sensitization of HL-60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals. Leukemia (Baltimore), 14: 602-611, 2000.
66. Ng, S. S. W., Tsao, M. S., Chow, S., and Hedley, D. W. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human cancer cells. Cancer Res., 60: 5451-5455, 2000.
67. Brognard, J., Clark, A. S., Ni, Y., and Dennis, P. A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res., 61: 3986-3997, 2001.
68. Yusta, B., Estall, J., and Drucker, D. J. Glucagon-like peptide-2 receptor activation engages bad and glycogen synthase kinase-3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinase. J. Biol. Chem., 277: 24896-24906, 2002.
69. Zhang, B. H., Tang, E. D., Zhu, T., Greenberg, M. E., Vojtek, A. B., and Guan, K. L. Serum- and glucocorticoid-inducible kinase SGK phosphorylates and negatively regulates B-Raf. J. Biol. Chem., 276: 31620-3166, 2001.
70. Xu, J., Liu, D., Gill, G., and Songyang, Z. Regulation of cytokine-independent survival kinase (C1SK) by the Phox homology domain and phosphoinositides. J. Cell Biol., 154: 699-705, 2001.
71. Welch, H., Eguinoa, A., Stephens, L. R., and Hawkins, P. T. Protein kinase B and rac are activated in parallel within a phosphatidylinositide 3OH -kinase-controlled signaling pathway. J. Biol. Chem., 273: 11248-11256, 1998.
72. Shimizu, T., O'Connor, P. M., Kohn, K. W., and Pommier, Y. Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res., 55: 228-231, 1995.
73. Hu, Y., Qiao, L., Wang, S., Rong, S. B., Meuillet, E. J., Berggren, M., Gallegos, A., Powis, G., and Kozikowski, A. P. 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block P13-K. Akt, and cancer cell growth. J. Med. Chem., 43: 3045-3051, 2000.